Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody
Posted: 14 August 2024 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the first participant has been successfully dosed in…
AusBiotech selected as Industry Partner Organisation for Australia’s Industry Growth Program
Posted: 14 August 2024 AusBiotech, Australia’s leading life science organisation, has been announced as an Industry Partner Organisation (IPO) under the Australian Government’s Industry Growth Program (IGP). AusBiotech welcomed its selection as an Industry Partner Organisation to provide…
Breakthrough Victoria CEO steps down
Posted: 14 August 2024 Breakthrough Victoria’s inaugural CEO, Grant Dooley, today announced he is stepping down after three successful years building and leading the Victorian Government’s technology innovation and commercialisation fund. Dooley will stay on to support BV’s…
IDT Secures New Contract with Sanofi Australia
Posted: 14 August 2024 IDT Australia Limited (ASX: IDT) (IDT or the Company) is pleased to announce that it has secured a follow-on contract with Sanofi Australia (Sanofi) worth between $2.5 million and $4 million for the preclinical…
Phase 2 trial shows significant improvements in Angelman syndrome
Posted: 14 August 2024 Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Angelman syndrome (AS). NNZ-2591 was safe and well tolerated as an oral liquid dose and…
Pfizer upgrades its plant in Melbourne to become one of the most advanced pharmaceutical production facilities in Australia
Posted: 13 August 2024 Australia is stepping up to the global fight against antimicrobial resistance, as Pfizer Australia announces a major upgrade to its manufacturing facility in Melbourne, Victoria. Pfizer has invested AU$150 million to offer advanced pharmaceutical…
Pfizer calls for action to attract global life sciences investment in Australia
Posted: 13 August 2024 Pfizer Australia is urging policy change to make Australia more attractive for global life sciences investment. In its new report, ‘Breakthrough Nation’, launched at the beginning of National Science Week (10-18 August), Pfizer highlights…
Clear line of sight to solving irreversible vision loss
Posted: 13 August 2024 One in 2 people with glaucoma doesn’t know they have it. And, shockingly, half of these people have had an eye test in the past year. Yet good 3-dimensional scanning technology, already used by…
$3.7 million funding boost for infection prevention and control in aged care
Posted: 13 August 2024 The Albanese Government is investing more than $3.7 million in funding towards targeted research into improving infection prevention and control (IPC) in aged care homes as part of its commitment to delivering high quality…
Amplia Receives R&D Tax Rebate Totalling $3.2 Million
Posted: 13 August 2024 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”) is pleased to advise that it has received a Research and Development (R&D) Tax Incentive refund of $3,177,718 for the 2023/2024 financial year. The refund…
One More Patient Shows Sustained Reduction in Tumour Size in Pancreatic Cancer Trial
Posted: 8 August 2024 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that a fourth patient enrolled in the Company’s Phase 2a clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer…
Granting of Key Chemical Form Patent in Europe and Japan
Posted: 8 August 2024 Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce the granting of a key patent in Europe and Japan. The patent, entitled A salt and crystal form of a FAK…
